Asosiy kontentga oʻtish
AkademIndex

Xizmatlar

← Ishga qaytish

Ushbu ish iqtibos qilgan ishlar

131 ta ish

Ish: The evolution of cellular-based immunotherapy in the treatment of gastric cancer: an overview of clinical trials

  1. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

    Freddie Bray, Mathieu Laversanne, Hyuna Sung +4

    MaqolaOchiq kirish202426 iqtibos
    ABI

  2. The paths and challenges of “off-the-shelf” CAR-T cell therapy: An overview of clinical trials

    Vahid Moradi, Azadeh Omidkhoda, Naser Ahmadbeigi

    Sharh maqola20239 iqtibos
    ABI

  3. Progress and pitfalls of gene editing technology in CAR-T cell therapy: a state-of-the-art review

    Vahid Moradi, Elnaz Khodabandehloo, Mehdi Alidadi +2

    Sharh maqola20248 iqtibos
    ABI

  4. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

    Nikhil C. Munshi, Larry D. Anderson, Nina Shah +25

    Maqola20217 iqtibos
    ABI

  5. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

    Shannon L. Maude, Theodore W. Laetsch, Jochen Buechner +32

    Maqola20187 iqtibos
    ABI

  6. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

    Yung‐Jue Bang, Eric Van Cutsem, A. Feyereislova +13

    MaqolaOchiq kirish20105 iqtibos
    ABI

  7. Focusing on exosomes to overcome the existing bottlenecks of CAR-T cell therapy

    Siheng Zhang, Linglong Peng, Yifei Chen +2

    Sharh maqola20244 iqtibos
    ABI

  8. Chimeric antigen receptor macrophages (CAR-M) sensitize HER2+ solid tumors to PD1 blockade in pre-clinical models

    Stefano Pierini, Rashid Gabbasov, Maria Cecília Oliveira-Nunes +28

    Maqola20254 iqtibos
    ABI

  9. Novel gene manipulation approaches to unlock the existing bottlenecks of CAR-NK cell therapy

    Fatemeh Dehghan, Yekta Metanat, Mandana Askarizadeh +2

    Sharh maqola20254 iqtibos
    ABI

  10. Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

    Philip W. Kantoff, Celestia S. Higano, Neal D. Shore +10

    MaqolaOchiq kirish20103 iqtibos
    ABI

  11. Development of mesothelin-specific CAR NK-92 cells for the treatment of gastric cancer

    Bihui Cao, Manting Liu, Jingjun Huang +17

    MaqolaOchiq kirish20213 iqtibos
    ABI

  12. A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab

    Prasad S. Adusumilli, Marjorie G. Zauderer, Isabelle Rivière +27

    MaqolaOchiq kirish20213 iqtibos
    ABI

  13. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results

    Changsong Qi, Jifang Gong, Jian Li +23

    MaqolaOchiq kirish20223 iqtibos
    ABI

  14. Chimeric Antigen Receptor T Cell Therapy Targeting Epithelial Cell Adhesion Molecule in Gastric Cancer: Mechanisms of Tumor Resistance

    Yanping Yang, Raymond H. Y. Louie, Janusz Puc +6

    MaqolaOchiq kirish20233 iqtibos
    ABI

  15. Combination therapy of DKK1 inhibition and <scp>NKG2D</scp> chimeric antigen receptor <scp>T</scp> cells for the treatment of gastric cancer

    Yipeng Zhang, Kaijie Liang, Xiaoyu Zhou +8

    Maqola20233 iqtibos
    ABI

  16. From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy

    Eleonora Pinto, Lisa A. Lione, Mirco Compagnone +8

    Sharh maqola20253 iqtibos
    ABI

  17. Sarlavhasiz

    Boshqa3 iqtibos
    ABI

  18. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances

    Karama Makni‐Maalej, Maysaloun Merhi, Varghese Inchakalody +8

    Sharh maqolaOchiq kirish20232 iqtibos
    ABI

  19. Hypoxia-Responsive CAR-T Cells Exhibit Reduced Exhaustion and Enhanced Efficacy in Solid Tumors

    Xiuxiu Zhu, Jun Chen, Wuling Li +8

    Maqola20232 iqtibos
    ABI

  20. Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial

    Changsong Qi, Chang Liu, Zhi Peng +31

    MaqolaOchiq kirish20252 iqtibos
    ABI

  21. Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango?

    Mohammad Kazemi, Maryam Sadri, Alireza Najafi +4

    Sharh maqolaOchiq kirish20222 iqtibos
    ABI

  22. Significantly increased anti‐tumor activity of carcinoembryonic antigen‐specific chimeric antigen receptor T cells in combination with recombinant human IL‐12

    Xiaowei Chi, Peiwei Yang, Erhao Zhang +9

    MaqolaOchiq kirish20192 iqtibos
    ABI

  23. EpCAM Signaling in Oral Cancer Stem Cells: Implications for Metastasis, Tumorigenicity, and Therapeutic Strategies

    Chuan‐Hsin Chang, Chung‐Che Tsai, Fu‐Ming Tsai +3

    Sharh maqola20252 iqtibos
    ABI

  24. Macrophage-Based Approaches for Cancer Immunotherapy

    Nicholas R. Anderson, Nicholas G. Minutolo, Saar Gill +1

    Sharh maqola20202 iqtibos
    ABI

  25. Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo

    Yanjing Song, Chuan Tong, Yao Wang +8

    Maqola20172 iqtibos
    ABI